Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Panelists discuss how the new nilotinib formulation offers improved convenience by eliminating fasting requirements which may enhance adherence, while emphasizing that clinicians should remain ...

Panelists discuss how innovative approaches to symptom monitoring incorporate multifaceted technology and team-based strategies, including electronic patient-reported outcome tools integrated with ...

Panelists discuss the importance of using liquid biopsy for detecting estrogen receptor 1 (ESR1) mutations rather than ...

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...